Press Release | Tue Apr 16, 2013 9:00am EDT

Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for LEVADEX® (dihydroergotamine) New Drug Application

* Reuters is not responsible for the content in this press release.